Anavex Life Sciences Corp (AVXL)

[Jonjones325]

I was doing some research into post trial access to investigational drugs and game across the document. It’s long but filled with great information about what goes in to the decision making process when deciding whether or not to give continued access to a drug after the clinical trial is over.

The criteria and rationale beginning on slide 15 is an interesting place to start when skimming the document.

So much goes into providing continued access. It’s not just ok. Here are some extra pills. Take care now.

It is a big deal that we are providing this access and speaks volumes. This also gives us some more insight into what some patients may have been experiencing. Happy speculating!

https://mrctcenter.org/wp-content/uploads/2017/12/2017-12-07-Post-Trial-Responsibilities-Toolkit-Version-1.1.pdf